Company Overview of Oligomerix, Inc.
Oligomerix, Inc. operates as biopharmaceutical companyand develops drugs for Alzheimer’s disease and other neurodegenerative disorders. The company was founded in 2006 and is based in New York, New York.
Audubon Business and Technology Center
Columbia University Medical Center
New York, NY 10032
Founded in 2006
Key Executives for Oligomerix, Inc.
Chief Executive Officer and President
Chief Commercial Officer and Director
Senior Director of Chemistry
Compensation as of Fiscal Year 2015.
Oligomerix, Inc. Key Developments
Oligomerix, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 10:30 AM
Apr 6 15
Oligomerix, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 10:30 AM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: James Moe, Chief Executive Officer and President.
Oligomerix, Inc. Announces the Relocation of Corporate Headquarters
Jan 14 14
Oligomerix, Inc. announced the relocation of its corporate headquarters to Valhalla, NY as of January 15, 2014 and expanded lease agreement for additional laboratory space at New York Medical College.
Taconic and Oligomerix to Collaborate on Tau Mouse Model Characterization for Use in Alzheimer's Disease Research
Dec 9 13
Taconic and Oligomerix, Inc. announced a collaboration to evaluate the utility of the Taconic tau mouse model (also known as the JNPL3 mouse) as a tool for pre-clinical testing of compounds for Alzheimer's disease. Used extensively in neurodegenerative disease research, the tau mouse model is part of the Taconic Transgenic Models(TM) (TTM(TM)) portfolio of in-licensed transgenic models available off-the-shelf in typical study quantities. For years Alzheimer's disease was believed to be caused by the toxic buildup of the amyloid beta protein. Most of the therapeutic methods under development have aimed to cut amyloid levels in order to prevent or delay onset of the disease. To date, all completed Phase III drug development programs based on the amyloid hypothesis have failed to meet their clinical endpoints. Oligomerix's work focuses on an alternate hypothesis that is rapidly advancing in the scientific community: that the accumulation of the tau protein, specifically tau oligomerization, is highly correlated with Alzheimer's disease progression and therefore an appropriate target for the development of disease-modifying therapeutics. Oligomerix will test this hypothesis using Taconic's tau mouse model that carries the transgene for the human mutation of the microtubule-associated protein -- tau. The Taconic tau model has been well-characterized for behavioral and motor disturbances related to the development of neurofibrillary tangles that are pathological hallmarks of Alzheimer's disease. Oligomerix will employ Taconic's model to develop assays to detect tau oligomers and evaluate the model's utility in preclinical testing using reference compounds already screened in cell assays.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 3, 2015
Most Searched Private Companies
Sponsored Financial Commentaries